Allergan to Unveil New Data

Allergan plc said pre-market Wednesday that new data on its chronic migraine treatment Botox will be featured in eight presentations at the annual meeting of the American Headache Society taking place in Boston from June 8 to 11.

The presentations consist of two oral presentations, three poster presentations on chronic migraine disease awareness and three posters containing long-term efficacy data on Botox as a treatment of chronic migraine from the Compel study. Botox represents the first and only Food and Drug Administration-approved preventive treatment for adult chronic migraine patients. It received FDA approval in 2010.

Leave a Comment